// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























7277 Abstracts

Correlates of High Platelet Reactivity on Clopidogrel in 8,533 Patients: An ADAPT-DES Substudy

Benjamin J. Vaccaro - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Venous thrombosis

Bivalirudin

Primary Endpoint Results of the TAXUS Liberte Post-Approval Study

David P. Lee - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Clopidogrel bisulfate

Clinical Outcomes after PCI Treatment of Very Long Coronary Lesions with the XIENCE V Everolimus Eluting Stent (EES): Pooled Analysis from the SPIRIT and XIENCE V USA Prospective Multi-Center Trials

James Hermiller Jr - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Primary Endpoint Results from the TAXUS Element Post-Approval Surveillance Study (TE-PROVE): 1-Year Outcomes in Unselected Patients Treated With a Thin-Strut, Platinum-Chromium, Paclitaxel-Eluting Stent

Corrado Tamburino - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Paclitaxel

Safety and Efficacy of Everolimus-Eluting Stents Versus Zotarolimus-Eluting Stents for 3-year of Follow-Up in Real-World Practice

Young Jin Youn - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

ZoMaxx

Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials

Run-Lin Gao - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

sirolimus

ENERGY 1,000 Patient Registry with a Thin Strut Bare Metal Stent with Passive Coating presenting Two Year Data

Ariel Roguin - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

N/A

Late Adverse Events After Implantation of Sirolimus-eluting Stent and Bare-metal Stent: 4-7 years follow-up of the CREDO-Kyoto Registry Cohort-2

Masahiro Natsuaki - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

sirolimus

Three-Year Safety And Efficacy Of Newer Generation Limus-Eluting Stents Compared To Bare Metal Stents and First-Generation Sirolimus-eluting Stents In Patients With Acute Coronary Syndrome

Alfazir Omar - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

ZoMaxx

Comparison of 5-year outcomes between drug-eluting and bare-metal stents in patients after acute myocardial infarction with or without diabetes

Wei-Chun Huang - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

N/A

Mid-term Clinical Outcomes after Polytetrafluoroethylene (PTFE)-covered Stent Implantation

Hiroyoshi Kawamoto - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Two-Year Clinical Outcome of Patients With Bifurcation Lesions Treated With Second-generation Zotarolimus-Eluting Resolute Stents and Everolimus-Eluting Xience V Stents in the Randomized TWENTE Trial

Kenneth Tandjung - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

ZoMaxx

Long-term Outcomes Of The New Generation Drug-Eluting Stents In Patients With Diabetes Mellitus And Single Vessel Disease

Chrysoula Patsa - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

ZoMaxx

Impact of Total Stent Length on Clinical Outcomes After Percutaneous Coronary Intervention With Biolimus-Eluting Stent Versus Everolimus-Eluting Stent

Takashi Hiromasa - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Six Years Consecutive Complete Follow-up Result of Sirolimus Eluting Stent (SES) Implanted Lesion.

Yohei Inoue - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

sirolimus

Multi Center, Prospective, Randomized, Single Blind, Consecutive Enrollment Evaluation a Novolimus-Eluting Coronary Stent System with Bioabsorbable Polymer Compared to a Zotarolimus-Eluting Coronary Stent System: Long Term (24- Month) Clinical Follow Up from the EXCELLA BD Study

Stefan Verheye - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

ZoMaxx

One year outcomes of percutaneous coronary intervention with a modern drug-eluting stent in patients with moderate and severe coronary calcification: A pooled analysis from the Nobori-2 and e-Nobori all-comer registries

Gert Richardt - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Biolimus A9

Long-Term Clinical Outcomes of Multiple Overlapping (60mm) Drug-Eluting Stent Implantation

Jung-Min Ahn - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Very-long term (11 years) follow up of a single center, complex cohort of patients treated exclusively with drug-eluting stents

Jose d Costa Jr - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Clinical Outcomes Following Resolute Zotarolimus-eluting Stent Implantation in Diabetic versus Non-Diabetic Patients Suitable for Percutaneous Coronary Revascularization: Insights From a Multicenter Italian Registry

Alfonso Ielasi - Transcatheter Cardiovascular Therapeutics (TCT) , 2013

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

ZoMaxx

Copyright © 2026. QuantiNova All rights reserved